LLY

1,134.66

+4.44%↑

JNJ

227.64

+1.53%↑

ABBV

222.32

+1.7%↑

UNH

396.33

+2.83%↑

MRK

119.16

+3.02%↑

LLY

1,134.66

+4.44%↑

JNJ

227.64

+1.53%↑

ABBV

222.32

+1.7%↑

UNH

396.33

+2.83%↑

MRK

119.16

+3.02%↑

LLY

1,134.66

+4.44%↑

JNJ

227.64

+1.53%↑

ABBV

222.32

+1.7%↑

UNH

396.33

+2.83%↑

MRK

119.16

+3.02%↑

LLY

1,134.66

+4.44%↑

JNJ

227.64

+1.53%↑

ABBV

222.32

+1.7%↑

UNH

396.33

+2.83%↑

MRK

119.16

+3.02%↑

LLY

1,134.66

+4.44%↑

JNJ

227.64

+1.53%↑

ABBV

222.32

+1.7%↑

UNH

396.33

+2.83%↑

MRK

119.16

+3.02%↑

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Deschisă

SectorSănătate

21.86 2.15

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

21.06

Maxim

22.05

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+67.68% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-252M 2.7B
Deschiderea anterioară	19.71
Închiderea anterioară	21.86

Sentimentul știrilor

By Acuity

29%

71%

75 / 344 Clasament în Healthcare

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iun. 2026, 23:22 UTC

Câștiguri

Principalele dinamici ale pieței

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 iun. 2026, 23:09 UTC

Acțiuni populare

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 iun. 2026, 20:51 UTC

Câștiguri

Costco Reports 15% Sales Growth in May

3 iun. 2026, 20:43 UTC

Câștiguri

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 iun. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 iun. 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 iun. 2026, 23:15 UTC

Market Talk

Câștiguri

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 iun. 2026, 22:08 UTC

Acțiuni populare

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 iun. 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 iun. 2026, 21:18 UTC

Câștiguri

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 iun. 2026, 21:15 UTC

Câștiguri

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 iun. 2026, 21:12 UTC

Câștiguri

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 iun. 2026, 21:09 UTC

Câștiguri

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 iun. 2026, 21:03 UTC

Câștiguri

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 iun. 2026, 20:43 UTC

Câștiguri

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 iun. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 iun. 2026, 20:37 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 iun. 2026, 20:35 UTC

Câștiguri

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Adj EPS $2.44 >AVGO

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q EPS $1.91 >AVGO

3 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Rev $22.19B >AVGO

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

67.68% sus

Prognoză pe 12 luni

Medie 34.86 USD 67.68%

Maxim 36 USD

Minim 34 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

75 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.